Correction

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (vol 102, pg 1773, 2023)

Journal

ANNALS OF HEMATOLOGY
Volume 102, Issue 9, Pages 2643-2644

Publisher

SPRINGER
DOI: 10.1007/s00277-023-05321-3

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Recommended

No Data Available
No Data Available